FSD Pharma’s Lucid-21-302 — an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS) — was found safe and well tolerated across multiple doses in healthy volunteers, according to interim data from a Phase 1 clinical trial
The newly released data are from the first four groups of participants who received a single ascending dose of the medication; however, no other details were shared by the company. Data from the fifth and final group are expected by the end of the month….READ MORE ABOUT IT HERE